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ABSTRACT: PMMA-based cements are the most used bone
cements in vertebroplasty and total hip arthroplasty. However,
they present several drawbacks, including susceptibility to
bacterial infection, monomer leakage toxicity, and high
polymerization temperature, which can all lead to damage to
the surrounding tissues and their failure. In the present study,
silver nanowires (AgNWs) have been introduced to bestow
antibacterial properties; chitosan (CS) to promote porosity
and to reduce the polymerization temperature, without
negatively aﬀecting the mechanical performance; and meth-
acryloyl chitosan (CSMCC) to promote cross-linking with
methyl methacrylate (MMA) and reduce the quantity of
monomer required for polymerization. Novel PMMA cements
were formulated containing AgNWs (0 and 1% w/w) and CS or CSMCC at various concentrations (0, 10, 20, and 30% w/w),
testing two diﬀerent ratios of powder and MMA (P/L). Mechanical, thermal, antibacterial, and cytotoxic properties of the
resulting composite cements were tested. Cements with concentrations of CS > 10% presented a signiﬁcantly reduced
polymerization temperature. The mechanical performances were aﬀected for concentrations > 20% with a P/L concentration
equal to 2:1. Concentrations of AgNWs as low as 1% w/w conferred antimicrobial activity against S. aureus, whereas bioﬁlm
formation on the surface of the cements was increased when CS was included in the preparation. The combination of CS and
AgNWs allowed a higher concentration of Ag+ to be released over time with enhanced antimicrobial activity. Inclusion of
AgNWs did not aﬀect cell viability on the scaﬀolds. In conclusion, a combination of CS and AgNWs may be beneﬁcial for
reducing both polymerization temperature and bioﬁlm formation, without signiﬁcantly aﬀecting mesenchymal stem cell
proliferation on the scaﬀolds. No advantages have been noticed as a result of the reducing P/L ratio or using CSMCC instead of
CS.
■ INTRODUCTION
Poly(methyl methacrylate) (PMMA) is currently the most
common bone cement used as a screw, prosthesis, or implant
ﬁxator in bone, ﬁller for bone cavities or skull defects, and
vertebroplasty in osteoporotic patients.1 PMMA beads are
combined with the liquid monomer (methyl methacrylate,
MMA) to form a slurry that, once injected, conforms to the
shape of its surrounding, allowing the distribution of implant
loads and the formation of strong mechanical bonds with bone
following monomer polymerization. Notwithstanding its
extensive application, PMMA use is hindered by a number of
limitations: lack of bioactivity, poor cement−bone integration,
stiﬀness mismatch between the bone and the cement, high
exothermic reaction temperature that can cause tissue necrosis,
and monomer toxicity characterized by a sudden drop in blood
pressure.2 Moreover, it has been reported that MMA can cause
allergic reactions through direct contact with the skin
(dermatitis) or through inhalation.3 Finally, an important risk
related to any biomaterial implantation is the occurrence of
infections that can lead to bioﬁlm formation and implant
failure.4,5
One strategy, employed to promote better PMMA bone
integration, is to increase the cement porosity with the
addition of biodegradable materials. For instance, chitosan can
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degrade, over time, leaving a rough and porous three-
dimensional (3D) structure in which the bone can grow,
promoting a more stable ﬁxation thanks to the improved
interlocking between the bone and cement.6 A further
advantage of the use of additives in bone cements is their
potential to dissipate the heat generated from the polymer-
ization reaction, minimizing the risk of bone necrosis; glycidyl
methacrylate (GMA) and trimethoxysilyl propyl methacrylate
(3MPMA) have been used to reduce polymerization temper-
ature.7 Alternatively, the functionalization of chitosan with
glycidyl methacrylate (GMA) to promote cross-linking with
MMA can have a similar eﬀect.7
Implantation of PMMA can be complicated by the
occurrence of osteomyelitis, a bacterial infection of the bone
frequently caused by Staphylococcus aureus.8 Infection can lead
to the destruction of the bone and consequently to increased
rates of treatment failure.9 Since more and more bacteria are
becoming resistant to antibiotics,10 attention has been shifting
to alternatives provided by nanotechnology, such as silver
nanowires (AgNWs). For example, oleic acid-capped AgNWs
(5.3 ± 2.3 nm) loaded into PMMA-based cements showed
antibacterial activity against methicillin-resistant Staphylococcus
aureus (MRSA) and S. aureus, at low concentrations of
0.05%.11 Slane et al. formulated a PMMA bone cement loaded
with silver NPs (30−50 nm) functionalized with poly-
(vinylpyrrolidone) at concentrations 0.25, 0.5, and 1%. No
antibacterial activity was found in suspension, but all
concentrations of AgNPs were able to signiﬁcantly reduce
bioﬁlm growth on the scaﬀold.12 However, all of these systems
presented a critical problem related to the extremely poor
biodegradability and interconnectivity of PMMA. If the plastic
does not degrade, silver will not come in contact with
physiological ﬂuids, oxidize, and have an eﬀect on the bacterial
cells.
In the present work, we report the preparation and
characterization of novel PMMA composites containing
chitosan (CS) or methacryloyl chitosan (CSMCC) to reduce
polymerization temperature, modify mechanical behavior, and
favor the formation of pores, and AgNWs that can oﬀer a
prolonged antibacterial eﬀected by a controlled silver ion
release, more sustained than spherical nanoparticles.13,14 We
further investigated the cytocompatibility, antibacterial, and
mechanical properties of the composites.
■ MATERIALS AND METHODS
Materials. DePuy SmartSet MV medium viscosity bone
cement was purchased from eSutures.com (Mokena, IL).
Chitosan from shrimp shell low viscosity (Mn 149.9 ± 4.7 kDa,
Mw 170.5 ± 4.9 kDa as determined by GPC-MALLS, degree of
deacetylation ∼85%, calculated by 1H NMR), poly-
(vinylpyrrolidone) powder (55 kDa), and all other reagents,
unless otherwise stated, were obtained from Sigma-Aldrich
(Irvine, UK). DMEM high glucose with glutaMAX and phenol
red, 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI),
glycerol, heat-inactivated fetal bovine serum, isopropanol,
MTT, PBS pH 7.4, phalloidin Dylight 550, trypan blue stain,
Table 1. Ratios Employed for the Formulation of Composite Cements, Together with the Average Mass Loss and Water
Uptake after 4 Weeks of Incubation in PBSa
cement type PMMA (g) MMA (mL) CS (g) CSMCC (g) AgNWs (%) mass loss (%) water uptake (%)
PMMA_1 2 1 0.09 ± 0.09 2.84 ± 1.03
PMMA _0.8 2 0.8 0.12 ± 0.12 3.44 ± 0.71
PMMA_AgNWs_1 2 1 1 0.23 ± 0.15 2.76 ± 0.66
PMMA_AgNWs_0.8 2 0.8 1 0.13 ± 0.22 2.77 ± 0.73
PMMA_CS10%_1 1.8 1 0.2 0.16 ± 0.25 3.86 ± 1.40
PMMA_CS10%_0.8 1.8 0.8 0.2 0.21 ± 0.24 3.99 ± 3.93
PMMA 2:1_CS10%_AgNWs 1.8 1 0.2 1 0.11 ± 0.12 7.15 ± 4.39b
PMMA 2:0.8_CS10%_AgNWs 1.8 0.8 0.2 1 0.16 ± 0.01 2.02 ± 1.31
PMMA 2:1_CS20% 1.6 1 0.4 0.62 ± 1.28 8.70 ± 2.44c
PMMA 2:0.8_CS20% 1.6 0.8 0.4 1.03 ± 0.65b 9.14 ± 2.43c
PMMA 2:1_CS20%_AgNWs 1.6 1 0.4 1 1.10 ± 2.07 10.30 ± 2.80c
PMMA 2:0.8_CS20%_AgNWs 1.6 0.8 0.4 1 0.93 ± 0.95b 9.76 ± 2.10c
PMMA 2:1_CS30% 1.4 1 0.6 3.66 ± 1.03c 13.36 ± 5.00c
PMMA 2:0.8_CS30% 1.4 0.8 0.6 4.00 ± 1.54b 8.65 ± 2.96c
PMMA 2:1_CS30%_AgNWs 1.4 1 0.6 1 2.61 ± 0.25d 11.59 ± 4.92c
PMMA 2:0.8_CS30%_AgNWs 1.4 0.8 0.6 1 3.29 ± 0.51b 8.42 ± 3.71b
PMMA 2:1_CSMCC10% 1.8 1 0.2 0.27 ± 0.27 3.41 ± 3.09
PMMA 2:0.8_CSMCC10% 1.8 0.8 0.2 0.21 ± 0.30 6.33 ± 4.29
PMMA 2:1_CSMCC10%_AgNWs 1.8 1 0.2 1 0.21 ± 0.16 5.49 ± 1.79
PMMA 2:0.8_CSMCC10_AgNWs 1.8 0.8 0.2 1 0.20 ± 0.07 2.18 ± 1.57
PMMA 2:1_CSMCC20% 1.6 1 0.4 0.32 ± 1.30 4.85 ± 0.97
PMMA 2:0.8_CSMCC20% 1.6 0.8 0.4 0.42 ± 0.51 9.22 ± 2.40c
PMMA 2:1_CSMCC20%_AgNWs 1.6 1 0.4 1 0.53 ± 0.21 7.60 ± 1.56b
PMMA 2:0.8_CSMCC20%_AgNWs 1.6 0.8 0.4 1 1.79 ± 0.30c 8.57 ± 2.19
PMMA 2:1_CSMCC30% 1.4 1 0.6 2.31 ± 0.97c 9.09 ± 3.36c
PMMA 2:0.8_CSMCC30% 1.4 0.8 0.6 2.28 ± 0.73b 8.79 ± 2.52d
PMMA 2:1_CSMCC30%_AgNWs 1.4 1 0.6 1 3.12 ± 1.01d 10.68 ± 1.84c
PMMA 2:0.8_CSMCC30%_AgNWs 1.4 0.8 0.6 1 3.62 ± 2.57b 9.64 ± 2.90d
aWeight loss and water uptake are reported as mean ± SD (n ≥ 3). Dunnett’s multiple comparison test was carried out to relate the results from
each sample to that of the control (PMMA_2:1). bp < 0.05. cp < 0.01. dp < 0.0001.
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silver nitrate, trypsin 0.25% EDTA with phenol red, and ×100
penicillin/streptomycin were from Fisher (Loughborough,
UK). ATPlite Luminescence ATP detection assay system was
purchased from PerkinElmer (Coventry, UK). Deuterium
chloride (D, 99.5%, DCL 20%), deuterium oxide (D, 99.9%),
and dimethyl sulfoxide-d6 (D, 99.9%) + 0.05% v/v
tetramethylsilane (TMS) were purchased from Cambridge
Isotope Laboratories (Tewksbury, MA).
Synthesis and Characterization of CSMCC. Chitosan
(CS, 2 g) was homogeneously dispersed in methanesulfonic
acid (11 mL) at 0 °C with overhead stirring for 2 h.
Methacryloyl chloride (MCC, 12 mL) was then added
dropwise into the chitosan dispersion, and the light brown
reaction mixture was further stirred for 4 h at 0 °C in the dark.
The reaction mixture was poured into cold water, and a light
cream precipitate was obtained after neutralization with
aqueous ammonia (35% v/v). The precipitate was dialyzed
against deionized water for 1 day, and the solid was recovered
by centrifugation at 2880g for 20 min at room temperature
(×3); the pellet was vacuum-dried at 40 °C and then
pulverized to aﬀord a ﬁne powder.
FT-IR spectra were recorded using a Varian FT-IR 640-IR
Instrument (Agilent, Santa Clara, CA), and spectra were
processed using Agilent Resolutions Pro software. For 1H
NMR analysis, CSMCC was dissolved in DMSO-d6 containing
0.5% TMS standard; chitosan was dissolved in D2O:DCl
(98:2); methacryloyl chloride (200 μL) was mixed with 800
μL of CDCl3. All of the samples were analyzed using a Jeol
Eclipse + 400 MHz NMR instrument (Oxford Instruments,
Oxford, UK). The degree of substitution in the reaction
product (DS%) was determined according to the following
formula
I I
I
DS(%)
( )
2
1
100v1 v2
a
= + × ×
where Iv1 and Iv2 are the integral intensities of the signals
assigned to the two vinylic protons present in methacryloyl
chloride, while Ia is the integral intensity of anomeric proton.
15
The powder particle size was determined by laser diﬀraction
using a Helos particle sizer coupled with a RODOS dry
dispersion unit and ASPIROS micro dose module (Sympatec
GmbH, Clausthal-Zellerfeld, Germany); a pressure of 2 bar
was used for the measurements.
The antibacterial properties of CS and CSMCC against S.
aureus were assessed in suspension. CS and CSMCC of 10 mg/
mL stock suspensions were prepared in sterile lysogeny broth
(LB), further sterilized under UV light overnight, and
sonicated for 20 min at 40 Hz before testing. Antibacterial
studies were carried out according to Ardila et al. with some
modiﬁcations.16 S. aureus (ATCC 25923) (106 CFU/mL) was
added to CS and CSMCC suspensions (0.2, 0.4, 0.8, 1, 2, 5,
and 10 mg/mL ﬁnal concentrations), and the volume was
brought to 2 mL with a sterile LB medium into 8 mL sterile
sealed bottles. After incubation at 37 °C and shaking at 200
rpm for 12 h (MaxQ 8000, Thermo Scientiﬁc), the bacterial
concentration was determined by measuring the optical density
of the suspension at 600 nm (OD600nm). Diﬀerent concen-
trations of the stock CS and CSMCC suspensions, as well as
pure LB, were used as blanks. The experiment was carried out
in triplicate (n = 3).
Synthesis and Characterization of AgNWs. AgNWs
were synthetized using the polyol method, as previously
described.14 AgNWs, with an average length of 5 μm and an
average diameter of 99 nm, were obtained.14
Preparation of Composite PMMA Cements. Cement
formulations with diﬀerent concentrations of additives and/or
powder to liquid monomer ratio (Table 1) have been prepared
and tested. Powders, in the selected ratios, were uniformly
mixed using a vortex (Fisherbrand) and then mixed with the
liquid monomer, at the required P/L ratio, by manual mixing
with a spatula, until the powders were fully wet. If AgNWs
were included in the preparation, freeze-dried AgNWs were
suspended in MMA by sonication for at least 20 min at 40 Hz
before mixing with the powders. When the mixture became
dough-like and easier to handle, the whole mixture was
transferred into a custom-made 10-well PTFE mold (6 mm
diameter, 12 mm height) and manually pressed. The cements
were allowed to cure for 1 h and then removed from the mold
and stored in a desiccator at room temperature until further
use.
Thermal Behavior. Setting temperature was measured
according to Chen et al. with minor adjustments.17 MMA was
added to the powders (3 g) and mixed until the dough was
fully wet. This was placed in plastic containers (3.5 cm
diameter × 1 cm height), and three thermocouples were
inserted a few mm under the surface of the dough to measure
and record the temperature at 5 s intervals for 25 min, using
data acquisition software, Pico Log from Pico Technology.
Temperature was plotted vs time to determine the peak
temperature (Tmax) and setting time (tset). The setting time
was the time point when the exothermic temperature reached
the midpoint temperature between the ambient (Tamb) and the
peak temperatures (Tmax). The setting temperature was
determined using the equation below
T
T T
2set
max amb= +
Degradation Studies. The degradability of the composite
cements was evaluated by determining weight loss, water
absorbance, and porosity changes following incubation in PBS.
Cement specimens were immersed in PBS (pH = 7.4) and
placed in an incubator at 37 °C for 4 weeks, shaking at 90 rpm
(Grant, Cambridge, UK); the PBS medium was changed every
week. At scheduled time points, samples were removed and
weighed (after the removal of any excess liquid). Samples were
then dried in a vacuum oven at 37 °C for 3 days before
measuring their ﬁnal weight. Water absorption and weight loss
were determined, applying the equations reported by Kim et
al.18 The total porosity and pore size were examined using
high-resolution X-ray computed tomography, XCT (Xradia
520 Versa, Carl Zeiss X-ray microscopy, CA), and the 3D data
was then analyzed with Avizo (9.3.0, FEI Company). The
images were collected using a 60 kVp tube voltage, a tube
current of 84 μA, and with a ZEISS LE1 ﬁlter in place. With an
isotropic voxel size of 6.11 μm, 1601 projections were collected
over 360° with an exposure time of 3 s per projection. After
reconstruction, a volume of interest was selected and a
threshold was applied to segment the pores. From the
segmented images, the volume of the pores and the total
porosity were calculated. Pores in contact with the edges of the
image were excluded from the analysis. Six samples per type
were tested for weight loss and water uptake. One sample per
type was analyzed three times for porosity and pore size
determination.
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Mechanical Behavior. Compressive tests were carried out
to evaluate ultimate compressive strength (UCS) and Young’s
modulus (E). Cements were prepared in the shape of cylinders
as described above, ends were sanded, and the diameter and
length were accurately measured using a Vernier caliper. Once
cement cylinders were embedded into metallic end caps with
epoxy resin using a customized alignment system, they were
tested at a speed of 0.02 mm/s up to 25% compression (MTS
Bionix, MTS Systems Corp., Eden Prairie, MN). Six samples
per cement type were tested, before and after degradation.
Morphological Characterization. The external surfaces
of cements before and after degradation were investigated
using a high-resolution scanning electron microscope (SEM,
Jeol JSM-6160L). Samples were gold-coated using a Polaron
e500 instrument (Quoram Technologies, UK). ImageJ
(version 1.8.0) software was used to determine the superﬁcial
pore size.
Silver Release Studies. The release of silver cations was
studied by incubating the cements in 5 mL of HPLC-grade
water at 37 °C with shaking (90 rpm). At scheduled times, 1
mL of supernatant was taken and substituted with 1 mL of
freshwater. The concentration of silver ions was determined by
a furnace atomic absorption spectrophotometer (VarianSpec-
trAA 220FS) at a wavelength and spectral bandwidth of 328.1
and 0.2 nm, respectively. A calibration curve was prepared by
diluting a silver standard (1 g/L) in deionized water (in the
range of 1−5 mg/L).
Bioﬁlm Formation on Cement Surfaces. Cements were
directly prepared in 96-well plates. The day after, they were
sterilized by treating with 70% EtOH for 30 min and washing
three times in sterile water. Then, they were irradiated with UV
light in a laminar ﬂow for 1 h. One hundred microliters of a 1
× 106 CFU/mL suspension of S. aureus in the LB medium
were plated in each well and incubated for 24 h at 37 °C. The
medium was removed, and each well was gently washed once
with PBS to remove loosely adherent bacteria. An MTT assay
was carried out to quantify the bacteria adhered to the cement
surface: 100 μL of 0.5 mg/mL of the MTT solution in PBS was
added to each well, and the plates were incubated for 1 h in the
dark.19 The supernatant was removed, and DMSO was added
to dissolve the formazan salts inside the cells. Then, the violet
solutions were transferred to a new 96-well plate, and the
absorbance was read at 570 nm using DMSO as blank. The
experiment was performed in triplicate.
Cytotoxicity Studies. Primary sheep mesenchymal stem
cells were obtained under project license number PPL70/8247,
and ethical approval was granted by the animal welfare and
ethical review board (AWERB) at the Royal Veterinary
College, London, UK. Cells were used between passages 2
and 5. Cells were grown in high-glucose DMEM supplemented
with 1% penicillin/streptomycin and 10% heat-inactivated
FBS. Cells were grown until 70% conﬂuence in an incubator at
37 °C and 5% CO2 and then detached with 0.25% trypsin−
EDTA. The cell suspension was centrifuged at 400g for 5 min
(Eppendorf Centrifuge 5702, UK), and the pellet was
resuspended in media, counted, and seeded onto the cylinders.
One day after manufacturing, cement cylinders were
submerged in complete DMEM at a weight-to-volume ratio
of 1:5 and incubated at 37 °C for 24 h.20 DMEM was removed
and ﬁltered through a 0.22 μm ﬁlter and frozen until further
use; these samples were used to test the biocompatibility of
cement extracts. Cells were grown overnight at a cell density of
5 × 103 cells/well in a 96-well plate. Then, the medium was
removed, and 100 μL of cement extracts were added to each
well followed by incubation for 24 and 48 h. At these
scheduled time points, the medium was removed and an MTT
assay was performed. The cells were plated for 4 h with 0.5
mg/mL MTT in a complete medium. Then, the medium was
Figure 1. Synthesis and characterization of CSMCC by FT-IR and 1H NMR. (A) Schematic representation of the synthesis of methacryloyl
chitosan (CSMCC). (B) FT-IR spectra of CS (black), MCC (dark gray), and CSMCC (light gray). (C) 1H NMR spectrum of CSMCC.
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removed, and 100 μL/well of DMSO was added. Absorbance
was read at 570 nm using DMSO as blank. The experiment
was performed in triplicate.
Cell proliferation on the surface of cements was determined
using an ATP bioluminescence assay. Cement cyliders were
prepared as described above. Cells (5000 cells/well) were
seeded, and their proliferation was measured with an ATP
assay, according to the manufacturer’s instructions (ATPlite,
PerkinElmer). Luminescence readings were taken in a 96-well
plate (SpectraMax i3x, Molecular DEVICES). Six replicates per
type were tested.
Morphological studies on cells were carried out by a
ﬂuorescence microscope after their culture on the cement disks
for 24 h. Cells were ﬁxed with paraformaldehyde 4% in PBS for
15 min, washed with PBS, permeabilized for 10 min in 0.1%
Triton X-100/PBS, washed twice with PBS, blocked with 2%
bovine serum albumin (BSA) in PBS for 1 h, washed twice
with PBS, stained with Phalloidin Dylight 550 in PBS (2 units/
mL, stock solution of 300 units/mL in methanol) for 1 h (300
μL, at room temperature), washed twice with PBS, stained
with DAPI 2 μg/mL in PBS for 10 min, and ﬁnally rinsed again
with PBS. Photographs were taken, using an epiﬂuorescence
microscope (Zeiss Axio Imager Z1) equipped with a
Hamamatsu HR camera and a color AxioCam MRc camera.
Images were processed by Volocity 6.3 software.
Statistical Analysis. Statistical analyses were performed
using GraphPad Prism 7.03 software. Details of the diﬀerent
statistical tests used are reported in the ﬁgure captions.
■ RESULTS
Physicochemical Characterization of CSMCC. CSMCC
was synthesized by modifying the primary hydroxyl group in
chitosan with a methacryloyl moiety, via a nucleophilic
substitution reaction carried out in a strongly acidic environ-
ment (methanesulfonic acid; pKa = −1.9) (Figure 1A). The
unreacted methacryloyl chloride was removed during the
washing steps as methacrylic acid ammonium salt.21 The
formation of CSMCC was conﬁrmed by FT-IR (Figure 1B):
the new peak at 1710 cm−1 is attributed to the CO bond in
the newly formed ester group. The chemical structure of
CSMCC was also conﬁrmed by 1H NMR (Figure 1C), with
vinylic proton signals appearing at δ 5.71 and 6.02 ppm, and
methyl protons corresponding to the methacryloyl group
appearing at δ 1.01 ppm. The 1H NMR spectrum also showed
a signal at δ 1.48 ppm from the three methyl H atoms (N-
acetyl glucosamine), a signal at δ 2.24 ppm from H2
(glucosamine), several overlapping signals (from δ 1.7 to 2.0
ppm) assigned to H3−H6 connected to the non-anomeric
C3−C6 carbons in the glucopyranose ring, and δ 2.3 ppm from
the anomeric proton. The degree of substitution of CSMCC
was determined as 25.7%.
In the formulation of composite bone cements, the particle
size and shape of the constituent powders are important to
guarantee homogeneous mixing and dispersion in the liquid
monomer. CS and CSMCC particles presented an irregular
shape (Figure S1) and had a signiﬁcantly higher particle size
than the PMMA powder (p < 0.05, Table 2) that was in the
range typically reported for commercial bone cements.22
Antibacterial Properties of CS and CSMCC Powders.
The bacteriostatic potential of CS and CSMCC powders was
tested against S. aureus by measuring the absorbance of the
bacterial suspension after 12 h of incubation in LB (Figure 2).
The compounds were studied in suspension rather than
solution as chitosan and modiﬁed chitosan were incorporated
in the PMMA cements as solids and are unlikely to dissolve at
physiological pH. While bacterial growth was detected for all
concentrations studied, results showed that concentrations ≥2
mg/mL were required to signiﬁcantly aﬀect bacterial growth.
In this respect, no diﬀerences were noticed between the
chitosan and modiﬁed chitosan.
Experimental Peak Temperature and Setting Time of
Cements. Commercially available acrylic bone cement is
typically activated by mixing a powder (P) and a liquid
component (L) at a P/L ratio of 2:1. The powder is generally
composed of PMMA beads, containing a radical initiator (e.g.,
benzoyl peroxide) and, when required, a radiopaque agent
(e.g., barium sulfate). The liquid contains the monomer methyl
methacrylate (MMA), a stabilizer (e.g., hydroquinone), and an
accelerator (e.g., N,N-dimethyl-p-toluidine) to encourage the
polymerization reaction to occur at room temperature (cold
curing cement).
When the two components are mixed together, the liquid
monomer polymerizes around the prepolymerized PMMA
particles (Figure 3) generating heat.23 In this study, we
recorded the polymerization temperature of the composite
bone cements and found that the peak polymerization
temperature decreased for all composites in comparison with
that of the PMMA 2:1 control (66.7 ± 8.7 °C) (Figure 4A,B).
Higher concentrations of CS and CSMCC (≥20%, in
particular) induced a signiﬁcant reduction in the polymer-
ization temperature (CS20%_0.8, p < 0.01; CSMCC20%_1 p
< 0.05). On the other hand, when the P/L ratio decreased to
Table 2. Average Particle Size, As Determined by Laser
Diﬀraction, Expressed as Sauter Mean Diameter (SMD) and
Volume Median Diameter (VMD) of CS, CSMCC, and
PMMA Powdersa
material SMD (μm) VMD (μm)
PMMA 34.6 ± 19.6 290.5 ± 171.6
CS 120.3 ± 21.8b 533.0 ± 32.1b
CSMCC 138.7 ± 53.9b 630.3 ± 39.9bc
aThe values are reported as mean ± SD (n = 3). Dunnett’s
multicomparison test was used to compare SMD and VMD of CS and
CSMCC with the ones of PMMA: bp < 0.05. t-test was used to
compare CS and CSMCC: cp < 0.05.
Figure 2. Antibacterial properties of CS and CSMCC. Optical density
(OD600 nm) of S. aureus suspensions in the presence of medium as
control (black bars), CS (light gray bars), and CSMCC (dark gray
bars) in suspension at diﬀerent concentrations. Data are reported as a
mean ± SD (n = 3). One-way ANOVA returned p < 0.05; results of
the Dunnett’s multiple comparison test are reported in the graph (*p
< 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). The t-test
performed between CS and CSMCC at diﬀerent concentrations
revealed no statistical diﬀerence (p > 0.05).
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2:0.8, the exothermic reaction temperature was not statistically
diﬀerent (p > 0.05). The lowest polymerization temperatures
for CS-enriched cements were recorded for PMMA CS30%
_0.8 (45.4 ± 3.4 °C) and PMMA CS30%_AgNWs_0.8 (44.2
± 1.4 °C), whereas for CSMCC for PMMA CSMCC30%_0.8
(44.9 ± 7.6 °C) and PMMA CSMCC30%_AgNWs_1 (45.0 ±
2.5 °C). According to ISO 5833:2002, the ideal setting time
for acrylic resin cements, depending on the usage, should be
between 3 and 15 min. With increasing concentrations of CS
and CSMCC (Figure 4C,D), the setting time increased from
667.2 ± 28.1 s (ca. 11 min) for PMMA_1 to 843.8 ± 2.9 s (ca.
14 min) for PMMA CS30%_1, remaining within the maximum
recommended time. The setting time was lower when the P/L
ratio was higher.
Figure 3. Morphology of PMMA cements. (A) Representative XCT reconstructed volume of a whole PMMA_2:1 cement and (B) cross section of
the same specimen. (C) SEM image of PMMA_2:1 cement surface; the arrow shows a PMMA bead within the solidiﬁed cement (see Figure S2 for
more images).
Figure 4. Setting properties of cements. Peak polymerization temperatures of PMMA cements containing CS (A) or CSMCC (B), and setting time
of PMMA-based cements, containing CS (C) or CSMCC (D), with diﬀerent ratios of P/L. Data are reported as a mean ± SD (n = 6). One-way
ANOVA returned p < 0.05; results of the Dunnett’s multicomparison test, used to compare all of the samples with the PMMA control, and results
of the t-test to compare samples with diﬀerent P/L ratios are reported in the graph (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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In Vitro Degradation Studies. The porosity and pore size
distribution of composite cements were evaluated by XCT.
During the polymerization process, voids formed as entrapped
air was unable to escape due to the cement paste viscosity.
Cements containing biodegradable materials, such as chitosan,
were expected to increase in porosity over time, and this was
also evaluated by XCT. Samples of the PMMA control and
composite cements containing 20% CS or CSMCC were
scanned. The PMMA-CS sample analyzed before degradation
showed a signiﬁcantly higher porosity than PMMA-only (p <
0.05), whereas the PMMA_2:1_CSMCC20% was not statisti-
cally diﬀerent. Furthermore, the cement containing CS and
CSMCC underwent degradation during a 4 week incubation
period in PBS (p < 0.05), while no signiﬁcant degradation was
shown in the PMMA-only cements (Figure 5A).
An increase in the pore size after 4 weeks of degradation was
observed only for PMMA_2:1_CS20% (p < 0.05) with the
average pore size increasing from 11.6 ± 13.4 to 13.1 ± 10.9
μm. PMMA cements before and after degradation had a
narrower pore size distribution in comparison to the cements
containing CS or CSMCC, both before and after degradation
(Figure 5B).
To further assess the composite cements, in vitro
degradation was evaluated by a gravimetric method. This
method is considered the golden standard for in vitro wear
assessment.24 This provides information about global mass
loss, though it does not give any information about the
distribution of wear within the material. As shown in Table 1,
PMMA-only cements showed a poor weight loss (0.09 ± 0.09
and 0.12 ± 0.12% for PMMA_2:1 and PMMA_2:0.8,
Figure 5. Pore volume and pore size of cements. Percentage pore volume (A) of PMMA (black), PMMA after 4 weeks (gray), CS_20% (red),
CS_20% after 4 weeks (orange), CSMCC_20% (dark green), and CSMCC_20% after 4 weeks (light green). Data are reported as a mean ± SD (n
= 3). T-test was performed between the same cement type before and after soaking ($p < 0.05). One-way ANOVA returned p < 0.05 (*) when
comparing the % pore volume of CS_20% to PMMA before degradation in PBS; results of the Dunnett’s multiple comparison test are reported in
the graph. One-way ANOVA returned p < 0.01 when comparing the % pore volume of CS_20% to PMMA after degradation in PBS; results of the
Dunnett’s multiple comparison test are reported in the graph (&&p < 0.01). (B) Pore diameter distribution for PMMA (black), PMMA after 4
weeks (gray), CS_20% (red), CS_20% after 4 weeks (orange), CSMCC_20% (dark green), and CSMCC_20% after 4 weeks (light green).
Figure 6. Compressive strength (MPa) and Young’s modulus (MPa) of composites cements, containing CS (A, C) and CSMCC (B, D). Results
are reported as a mean ± SD (n = 6). For compressive strength, one-way ANOVA returned p < 0.05; results of Dunnett’s multicomparison test
(used to compare all of the samples with the PMMA_2:1) are reported in the graph (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
Unpaired t-test was performed to compare each formulation containing a weight-to-volume ratio of 2:1 with the respective formulation containing a
weight-to-volume ratio of 2:0.8 ($p < 0.05, $$p < 0.01). For Young’s modulus, one-way ANOVA returned p < 0.05; results of Dunnett’s
multicomparison test, used to compare all samples with the PMMA control, are reported in the graph (*p < 0.05). Unpaired t-test was performed
to compare each formulation containing a weight-to-volume ratio of 2:1 with the respective formulation containing a weight-to-volume ratio of
2:0.8 ($p < 0.05).
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respectively), whereas CS- and CSMCC-based cements
presented higher weight loss, which increased with the increase
of the polysaccharide concentration, as expected. For instance,
the calculated weight loss for PMMA_CS_2:1 samples
increased from 0.16 ± 0.25 to 0.68 ± 0.57 and ﬁnally 3.66
± 1.03% for 10, 20, and 30% chitosan contents, respectively.
No statistical diﬀerence between the two MMA concentrations
was found. Water absorbance increased with the increase of CS
or CSMCC up to nearly 13% (Table 1). Similar trends are
reported in the literature for chitosan-based polyester and
poly(methyl methacrylate) cements.25 This trend can be
justiﬁed in two diﬀerent ways: the presence of chitosan that
is hygroscopic and promoted the water absorption by the
scaﬀold, while this was not possible in PMMA-only cements
that are hydrophobic. Alternatively, higher porosity and/or
interconnectivity of the material, due to chitosan degradation,
could promote water retention within the scaﬀold (as
suggested from XCT). No statistical diﬀerence was determined
between CS- and CSMCC-based cements (p < 0.05).
Mechanical Properties. In this study, we incorporated
increasing mass ratios of CS or CSMCC to study how the
mechanical properties of PMMA cements are aﬀected. Surgical
PMMA cement is brittle in nature. It is therefore weak under
tension but quite strong in compression and is capable of
yielding under uniaxial compression. The compressive strength
and elastic modulus of composite cements generally decreased,
increasing the mass ratio of CS or CSMCC in the mixture
(Figure 6). This trend is in good agreement with Dunne et al.
for PMMA bone cements (Palacos R) loaded with chitosan, at
lower concentrations (1, 3, and 5% w/w),26 and Tan et al. who
incorporated 20% chitosan into PMMA bone cements (CMW
endurance bone cement).27 When AgNWs were included in
the formulation, no statistical diﬀerences were reported. This
trend has also been reported by Slane et al., who incorporated
1.0% w/w silver nanoparticles into acrylic bone cements.12
When the ratio between the powder and liquid was 2:1, the
compressive modulus and elastic modulus were signiﬁcantly
decreased with the inclusion of 30% CS. This can be attributed
to the presence of less chemical links inside the cements and
possibly the presence of loose powder. On the other hand,
when the ratio between the powder and liquid was 2:0.8, the
compressive strength was signiﬁcantly diﬀerent also for lower
concentrations of CSMCC (20%).
The mechanical performance was also evaluated after the in
vitro degradation study was carried out for 4 weeks; however,
no signiﬁcant diﬀerences were determined with an unpaired t-
test (p > 0.05) (Figures S3 and S4).
Silver Release from Composite Cements. A release
study of silver ions was performed in deionized water for a
period of 21 days, and the cumulative release proﬁles are
presented in Figure 7. The bone cements loaded with AgNWs
continuously released Ag+ ions to the surrounding water with
the amount of silver increasing signiﬁcantly within the ﬁrst day
and then reaching a plateau. No statistical diﬀerence was found
between the diﬀerent cements studied (p > 0.05), even though
the cements containing CS/CSMCC presented a higher Ag+
release at any time point.
Antibacterial Properties of Cements. The antimicrobial
properties of the composite bone cements were determined
using an MTT assay after 24 h of incubation in an S. aureus
suspension. PMMA-only cements presented lower bacterial
attachment than the cements containing CS or CSMCC
powders at concentrations higher or equal to 20% (Figure 8).
On the other hand, when AgNWs were incorporated within
the formulation, they induced a signiﬁcant reduction of the
viable bacteria attached to the cement for all of the studied
formulations (p < 0.05), except for CS and CSMCC at 10%.
Evaluation of the Cytocompatibility of the Compo-
site Cements. Cytocompatibility was evaluated both on
cement eluates (Figure 9A,B) and directly on composite
PMMA cements (Figure 9C,D). The use of eluates simulates
the postsurgical release of toxic leachables into the surrounding
bony environment. Moreover, through serial dilutions, it is
possible to evaluate the dose-dependent eﬀect. Cytocompat-
ibility was assessed after 24 and 48 h of incubation of cells with
the eluates, and no statistical diﬀerence was found (p > 0.05),
except for PMMA_AgNWs_1 (p < 0.01). The cell viability at
24 h was > 80% for all cements with P/L 2:1; except for the
cements containing 20% of CS or CSMCC and AgNWs that
caused a signiﬁcant decrease in cell viability: PMMA_CS20%
_AgNWs_1 (51.6 ± 31.5%), PMMA_CSMCC20%
_AgNWs_1 (55.6 ± 36.6%), PMMA_CS20%_AgNWs_0.8
(52.4 ± 9.3%), and PMMA_CSMCC20%_AgNWs_0.8 (45.2
± 30.9%). Diluted extracts (50%) always maintained cell
viability > 80%, indicating a dose-dependent eﬀect (Figure S5).
When comparing the two diﬀerent concentrations of MMA at
diﬀerent time points, no statistical diﬀerence was found (p >
0.05). Overall, these results suggest that with the addition of
CS/CSMCC (and consequently the reduction of bone cement
powder) in the formulation, less liquid cement could react with
the initiator and more toxic leachables were released from the
cements over time.
Cell proliferation at 1 and 3 days of seeding cells onto the
cement surface was also evaluated. It was found that there was
signiﬁcantly higher cell proliferation between days 1 and 3 for
cells seeded on samples containing PMMA-only both with (p <
0.05) and without AgNWs (p < 0.0001). While for samples
containing CS/CSMCC in low amounts, only the following
samples showed increased proliferation: PMMA_CS10% (p <
0 . 0001) , PMMA_CS10%_AgNWs (p < 0 . 05 ) ,
PMMA_CSMCC10% (p < 0.05), and PMMA_CS20% (p <
0.05). For higher concentrations of polysaccharide, prolifer-
ation did not statistically increase (p > 0.05). These results are
similar to those reported by Tan et al. who loaded PMMA-
based cements with chitosan powder at 20% w/w (PMMA-
C).28 Compared with PMMA, PMMA-C cements presented a
lower proliferation rate. These results are also in agreement
with the cytotoxicity studies performed on the extracts; the
Figure 7. Cumulative release of silver ions from bone cements:
PMMA_AgNWs_1 (black), PMMA_AgNWs_0.8 (red),
PMMA_CS20%_AgNWs_1 (blue), PMMA_CS20%_AgNWs_0.8
( g r e e n ) , PMMA_CSMCC20%_AgNWs_1 ( y e l l ow ) ,
PMMA_CSMCC20%_AgNWs_0.8 (purple). Data are reported as a
mean ± SD (n = 3). One-way ANOVA, at 21 days, returned p > 0.05.
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increased ratio between the bone cement liquid and bone
cement powder decreased cell viability, over time.
On the other hand, the inclusion of AgNWs did not interfere
with cell proliferation in comparison to their controls.
■ DISCUSSION
Carefully designing composite biomaterials is paramount in
overcoming limitations of currently used products such as
PMMA. In the present study, a number of strategies have been
combined to address the main limitations aﬀecting the
performance of PMMA cements. The strategies included 1.
the addition of biodegradable chitosan to increase material
porosity and degradability, thus favoring PMMA/bone
integration and tuning the mechanical properties of the
material; 2. the use of methacrylated chitosan to reduce
polymerization temperature and avoid the risk of tissue
necrosis; and 3. the addition of AgNWs to bestow antibacterial
properties.
Methacryloyl chitosan (CSMCC) was successfully obtained
with a degree of substitution of 25% and used in the
formulation of composite cements. Before addition to the
composite cements, both the chitosan and modiﬁed chitosan
were tested to evaluate their antimicrobial properties in the
solid form. The antibacterial activity observed for all chitosan
powders studied was lower than that reported in the literature.
This was expected, as the powders were in suspension at a
neutral pH, while published studies have been carried out at a
pH lower than the pKa of chitosan.
29 In an acidic environment,
chitosan is protonated and thus capable of interacting with the
negatively charged bacterial surface.16 These results conﬁrm
the need to add, to composite PMMA cements, other
components with antimicrobial properties beside chitosan, to
Figure 8. Inhibition of bioﬁlm formation expressed as viable cell count. Absorbance relative to the number of bacterial cells on cement (P/L 2:1)
surfaces obtained by an MTT assay after 24 h. (A) PMMA-based cements containing CS. (B) PMMA-based cements containing CSMCC. Data are
reported as mean ± SD (n = 4). One-way ANOVA returned p < 0.05; results of the post hoc Tukey’s multicomparison test are reported in the
graph (*p < 0.05). Unpaired t-test was performed to compare each formulation with and without AgNWs. * represents p < 0.05, ** represents p <
0.01, *** represents p < 0.001, and **** represents p < 0.0001.
Figure 9. Cytotoxicity of cements on mesenchymal stem cells. Cytotoxicity was tested against the cement eluates (A, B) and by direct contact of
cells with cements (C, D). Toxicity of extracts from cements of P/L ratios 2:1 (A) and 2:0.8 (B) at 24 (left column) and 48 h (right column). Data
are reported as mean ± SD (n ≥ 3). One-way ANOVA returned p < 0.05; results of the post hoc Tukey’s multicomparison test are reported in the
graph (*p < 0.05). Unpaired t-test was performed to compare each formulation with or without AgNWs. ATP assay for MSCs after 1 day and 3
days of incubation on CS cements (C) and CSMCC cements (D). One-way ANOVA was carried out to compare ATP levels of each cement to
PMMA 2:1 at days 1 and 3 and showed a statistical diﬀerence (p < 0.05). Results of Dunnett’s multicomparison are reported in the graph; in
particular, $ p < 0.05, $$ p < 0.01, $$$ p < 0.001, and $$$$ p < 0.0001, at day 1. £ p < 0.05, ££ p < 0.01, £££ p < 0.001, and ££££ p < 0.0001, at day 3.The t-
test was performed to compare each type of cement at 1 and 3 days (*p < 0.05, **** p < 0.0005).
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obtain an eﬀective action against possible bacterial infections.
Once established that CS and CSMCC on their own were not
able to provide beneﬁts in terms of the antimicrobial activity,
we evaluated their eﬀect on the temperature and time of
polymerization. According to ISO 5833:2002, the maximum
polymerization temperature for acrylic resin cements should be
≤90 °C; temperatures lower than 56 °C would ensure reduced
tissue necrosis at the interface between the cement and the
natural tissue. Our study showed that the addition of CS and
CSMCC reduced the peak polymerization temperature by heat
dissipation throughout the bone cement material as previously
shown for other additives, such as MgO, hydroxyapatite, CS,
BaSO4, and SiO2.
30 The addition of the polysaccharide also
increased the setting time but within acceptable limits. This
experiment revealed that the modiﬁcation of chitosan to
CSMCC did not aﬀord any advantage in terms of signiﬁcantly
reduced polymerization temperature; the simple addition of
chitosan was suﬃcient to achieve this goal. Similarly, the use of
CSMCC did not aﬀect water absorption and degradation of
the composite cements. However, the use of the poly-
saccharides allowed us to obtain cements with tunable
degradation properties. Similarly, it was expected that chitosan
would help modulate the mechanical properties of the
composite cements. This would help overcome one of the
major problems related to standard PMMA cements that is the
mismatch between the mechanical properties of the cement
and the bone, especially in the case of osteoporotic bone,31
with a consequently increased risk of fracture of the adjacent
vertebral bodies, in cases of vertebral augmentation with
PMMA.32 It has been previously shown that the mechanical
properties of PMMA-based bone cements can be decreased by
introducing porosity or using additives.26,33 The addition of CS
and CSMCC resulted in reduced compressive strength and
Young’s modulus once the concentration of the additive
reached 20% w/w. This can be due to a combination of
increased porosity and incomplete monomer polymerization
caused by the presence of the polysaccharide in the setting
mixture and in correlation with the observed reduced
polymerization temperature. One of the aims of the study
was also to create cements that would inhibit the formation of
a bioﬁlm in vivo. The lack of antibacterial activity of chitosan
powders loaded into PMMA cements was expected as already
highlighted by Dunne et al.; this behavior may be due to the
physical form of CS or CSMCC powders that act as physical
supports for the attachment of bacteria, as previously reported
for chitosan microspheres, powders, and ﬂakes.16,34 For this
reason, AgNWs were added as the antimicrobial agent. We
previously demonstrated that AgNWs are able to provide a
sustained release of silver ions on their own;14 current data
support this; in fact, all composite cements released Ag+ with a
similar proﬁle with the total cumulative release well below the
potential toxic limit of 10 ppm for human cells.35 Our ﬁndings
show that AgNWs can reduce bioﬁlm formation on bone
cements; these results are in good agreement with those
reported by Prokopovich et al. who showed a signiﬁcant
reduction of bacterial attachment on PMMA cements loaded
with 0.05% silver nanospheres (5.3 ± 2.3 nm).11 Chitosan and
AgNW combinations in the PMMA cements, similarly to our
previous study on composite hydrogels, show that the activity
of AgNWs is potentiated by the presence of chitosan due to a
synergic activity.14 The same combination provides good cell
viability when the concentration of chitosan is lower than 20%
w/w.
■ CONCLUSIONS
CS and CSMCC were added to PMMA cements in
concentrations ranging from 10 to 30% w/w. The reduction
of the polymerization temperature was found to be dose-
dependent and signiﬁcantly reduced for concentrations > 10%.
An increased water uptake and weight loss were observed in
cements containing chitosan or modiﬁed chitosan in
comparison to the controls, and the eﬀect was more noticeable
with an increase in their concentration. The compressive
strength and elastic modulus generally decreased with an
increasing mass ratio of CS or CSMCC in the mixture; the
same trend was observed for cytotoxicity. No statistical
diﬀerences were observed between the materials containing
either CS or CSMCC. The results of the in vitro studies
demonstrated that the incorporation of AgNWs in PMMA−
chitosan cements in a concentration of 1% w/w can be a viable
approach to prevent S. aureus infections on the scaﬀold, while
not aﬀecting their mechanical properties and cytocompatibility.
These formulations provided a sustained release of Ag+ ions,
suggesting potential antimicrobial activity over an extended
period of time. Overall, this study suggests that the inclusion of
CS/CSMCC (between 10 and 20%) and AgNWs (1%) in the
existing commercial materials can provide bone cements with
good cytocompatibility and appropriate thermal, mechanical,
and antibacterial properties.
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